image
Healthcare - Biotechnology - NASDAQ - US
$ 14.38
-2.38 %
$ 2.4 B
Market Cap
10.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ACAD stock under the worst case scenario is HIDDEN Compared to the current market price of 14.4 USD, ACADIA Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ACAD stock under the base case scenario is HIDDEN Compared to the current market price of 14.4 USD, ACADIA Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ACAD stock under the best case scenario is HIDDEN Compared to the current market price of 14.4 USD, ACADIA Pharmaceuticals Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ACAD

image
$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
958 M REVENUE
31.85%
231 M OPERATING INCOME
414.52%
226 M NET INCOME
469.50%
158 M OPERATING CASH FLOW
844.31%
-30.5 M INVESTING CASH FLOW
-95.44%
6.84 M FINANCING CASH FLOW
-72.76%
260 M REVENUE
3.67%
154 M OPERATING INCOME
385.09%
144 M NET INCOME
338.71%
40.4 M OPERATING CASH FLOW
-36.15%
122 M INVESTING CASH FLOW
248.14%
1.97 M FINANCING CASH FLOW
634.70%
Balance Sheet ACADIA Pharmaceuticals Inc.
image
Current Assets 938 M
Cash & Short-Term Investments 756 M
Receivables 105 M
Other Current Assets 77.6 M
Non-Current Assets 249 M
Long-Term Investments 0
PP&E 50.8 M
Other Non-Current Assets 199 M
63.65 %8.81 %6.54 %4.28 %16.72 %Total Assets$1.2b
Current Liabilities 395 M
Accounts Payable 16.2 M
Short-Term Debt 9.96 M
Other Current Liabilities 369 M
Non-Current Liabilities 60.1 M
Long-Term Debt 42 M
Other Non-Current Liabilities 18.1 M
3.56 %81.04 %9.24 %3.97 %Total Liabilities$455.0m
EFFICIENCY
Earnings Waterfall ACADIA Pharmaceuticals Inc.
image
Revenue 958 M
Cost Of Revenue 81.8 M
Gross Profit 876 M
Operating Expenses 645 M
Operating Income 231 M
Other Expenses 4.34 M
Net Income 226 M
1b1b900m900m800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00958m(82m)876m(645m)231m(4m)226mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
91.46% GROSS MARGIN
91.46%
24.10% OPERATING MARGIN
24.10%
23.64% NET MARGIN
23.64%
30.90% ROE
30.90%
19.07% ROA
19.07%
25.22% ROIC
25.22%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ACADIA Pharmaceuticals Inc.
image
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 226 M
Depreciation & Amortization 5.66 M
Capital Expenditures -523 K
Stock-Based Compensation 67 M
Change in Working Capital 0
Others -141 M
Free Cash Flow 157 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ACADIA Pharmaceuticals Inc.
image
Wall Street analysts predict an average 1-year price target for ACAD of $24.5 , with forecasts ranging from a low of $20 to a high of $31 .
ACAD Lowest Price Target Wall Street Target
20 USD 39.08%
ACAD Average Price Target Wall Street Target
24.5 USD 70.38%
ACAD Highest Price Target Wall Street Target
31 USD 115.58%
Price
Max Price Target
Min Price Target
Average Price Target
3232303028282626242422222020181816161414Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership ACADIA Pharmaceuticals Inc.
image
Sold
0-3 MONTHS
243 K USD 3
3-6 MONTHS
415 K USD 3
6-9 MONTHS
779 K USD 3
9-12 MONTHS
349 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'. businesswire.com - 3 weeks ago
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 3 weeks ago
Acadian upgraded to Equal Weight from Underweight at Morgan Stanley Morgan Stanley upgraded Acadian Asset Management to Equal Weight from Underweight with a price target of $26, up from $25. The company's skew to overseas assets will insulate its possible downside to earnings relative to peers, the analyst tells investors in a research note. Further, the firm sees potential increased appeal of Acadian's non-U.S. equity strategies to the extent investors increase allocations to rest of world. https://thefly.com - 3 weeks ago
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' em. businesswire.com - 1 month ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat wi. businesswire.com - 1 month ago
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an. businesswire.com - 1 month ago
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago. zacks.com - 1 month ago
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised) ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales. zacks.com - 1 month ago
Acadia Pharmaceuticals Ends FY2024 On Solid Footing ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see solid growth from its two products on the market and has also build up a large amount of net cash on its balance sheet. ACADIA Pharmaceuticals is also advancing several key assets within its developmental pipeline. seekingalpha.com - 2 months ago
Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceu. businesswire.com - 2 months ago
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales. zacks.com - 2 months ago
8. Profile Summary

ACADIA Pharmaceuticals Inc. ACAD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.4 B
Dividend Yield 0.00%
Description ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Contact 12830 El Camino Real, San Diego, CA, 92130 https://www.acadia-pharm.com
IPO Date May 27, 2004
Employees 653
Officers Mr. James K. Kihara Senior Vice President of Finance Mr. Thomas Andrew Garner Chief Commercial Officer Dr. Kevin R. Oliver Ph.D. Chief Business Officer Ms. Jennifer J. Rhodes J.D. Chief Legal Officer & Secretary Mr. Stephen R. Davis J.D. Consultant Dr. Elizabeth H.Z. Thompson Ph.D. Head of Research & Development Mr. Rob Ackles Chief People Officer Mr. Mark C. Schneyer Executive Vice President & Chief Financial Officer Ms. Catherine E. Owen Adams Chief Executive Officer & Director